一级预防他汀管理推荐:国际风险评分间的差异
本研究通过模拟人群比较北美与欧洲常用风险算法在识别需他汀治疗或考虑风险增强/减弱因素患者中的差异。结果显示,三种风险等级的算法间一致性为19%至85%,仅SCORE2高风险和极高风险版本识别出男女高风险比例相等。风险算法在风险估计、他汀推荐和辅助检查使用上存在显著差异。
要点
- 不同风险算法对同一患者的风险分层一致性仅19%–85%。
- 仅SCORE2高风险和极高风险版本识别男女高风险比例相等。
- 风险算法差异影响他汀推荐及辅助检查决策。
核心结论
- 风险算法在风险估计、他汀治疗推荐和辅助检查使用上差异显著,即使患者风险因素相同。
研究设计与样本
- 模拟人群研究,纳入7680名男女各半、年龄45-70岁、总胆固醇3.5-7.0 mmol/L、高密度脂蛋白胆固醇0.6-2.2 mmol/L、收缩压100-170 mmHg的个体,分别用FRS、PCE、四种SCORE2版本和MESA算法评估风险。
主要发现
- 三种风险等级(高、中、低)的算法间一致性范围为19%至85%。
- 除MESA外,中危比例分别为25%(SCORE2极高风险区域)、32%(FRS)、39%(PCE)和45%(SCORE2低风险区域)。
- 仅SCORE2高风险和极高风险版本识别出男女高风险比例相等。
关键数值与推荐
- 高风险、中风险和低风险的定义分别基于FRS、PCE、四种SCORE2版本和MESA算法(0-1000 Agatston单位)。
临床怎么用
- 临床选择风险算法时应意识到不同算法可能导致风险分层和治疗推荐差异。
- 对于中等风险患者,需结合风险增强和减弱因素辅助决策。
局限性
- 研究基于模拟人群,可能无法完全反映真实临床人群的复杂性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Statin recommendations in primary prevention depend upon risk algorithms. Moreover, with intermediate risk, risk enhancers and de-enhancers are advocated to aid decisions. The aim of this study was to compare algorithms used in North America and Europe for the identification of patients warranting statin or consideration of risk enhancers and de-enhancers. METHODS: A simulated population (n = 7680) equal in males and females, with/without smoking, aged 45-70 years, total cholesterol 3.5-7.0 mmol/L, high-density lipoprotein cholesterol 0.6-2.2 mmol/L, and systolic blood pressure 100-170 mmHg, was evaluated. High, intermediate, and low risks were determined using the Framingham Risk Score (FRS), Pooled Cohort Equation (PCE), four versions of Systematic Coronary Risk Evaluation 2 (SCORE2), and Multi-Ethnic Study of Atherosclerosis (MESA) algorithm (0-1000 Agatston Units). RESULTS: Concordance for the three levels of risk varied from 19% to 85%. Both sexes might be considered to have low, intermediate, or high risk depending on the algorithm applied, even with the same burden of risk factors. Only SCORE2 (High Risk and Very High Risk versions) identified equal proportions of males and females with high risk. Excluding MESA, the proportion with moderate risk was 25% (SCORE2, Very High Risk Region), 32% (FRS), 39% (PCE), and 45% (SCORE2, Low Risk Region). CONCLUSION: Risk algorithms differ substantially in their estimation of risk, recommendations for statin treatment, and use of ancillary testing, even in identical patients. These results highlight the limitations of currently used risk-based approaches for addressing lipid-specific risk in primary prevention.
引用
- Mancini, Ryomoto, Yeoh, et al. Recommendations for statin management in primary prevention: disparities among international risk scores. Eur Heart J. 2024. PMID: 37638490. doi:10.1093/eurheartj/ehad539
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。